Dish of the day

Joiners: 

No joiners today. 

Leavers: 

No leavers today. 

 

What’s cooking in the IPO kitchen?** 

Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.

 

Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.

 

Banquet Buffet*** 

Barkby Group 8.25p  £11.9m (BARK.L) 

The Company engaged in real estate development, consumer and hospitality businesses, and life sciences announces that its subsidiary, Cambridge Sleep Sciences (CSS) the science-based sleep technology business behind SleepEngine®, has granted a five-year global license, to Mammoth International Ltd., (MIL) enabling it to manufacture a Smart Mattress using CSS's SleepEngine® platform. Under the terms of the Agreement, MIL will incorporate CSS's sleep technology into a new Smart Mattress product line. MIL will pay CSS a royalty of £75 per single mattress and £150 per double. Manufacturing is expected to commence in the next six months and expects to produce c.5000 mattresses in the year. 

 

Bivictrix Therapeutics 14p  £11.6m (BVX.L) 

A biotechnology company developing novel, next-generation anti-cancer precision Antibody Drug Conjugates announces its unaudited interim results for the six months ended 30 June 2023. Loss after tax for the period was £1.2m (H1 2022: £1.3m) reflected by investments in R&D of £1.1m (H1 2022: £1.2m) and administrative expenses of £0.3m. The Group closed the period with a cash balance of £1.9m at (H1 2022: £4.5m). The Group continued its progression of the BVX002 and BVX003 programmes to broaden their therapeutic pipeline and further evaluate their proprietary approach's utility in targeting multiple solid tumour indications. The Group has been granted a US patent providing broad protection for BVX001 through to 2039. 

 

Good Energy Group 192.5p  £32.5m (GOOD.L) 

The 100% renewable electricity supplier and innovative energy services provider announces its interim results for the six months ended 30 June 2023. Revenue increased 45.6% to £156.1m (H1 2022: £107.6m) and as a result the gross profit increased 168% to £32.7m (H1 2022: £12.2m) with a gross profit margin of 20.9% (H1 2022: 11.4%). The Company announced an operating profit of £14.1m (H1 2022: £0.5m loss) and reported a profit after tax of £12.0m (H1 2022: £0.3m). The Company holds cash of £34.9m. The Company completed its acquisition of WessexECO Energy in June 2023, an established UK based solar installation business for £2.5m. The Company’s  FY23 expectations remain unchanged. 

 

IQE 18.74p  £180.2m (IQE.L) 

The supplier of compound semiconductor wafer products and advanced material solutions to the semiconductor industry, announces a strategic collaboration with VisIC Technologies, a provider of GaN (Gallium Nitride) power solutions. IQE and VisIC Technologies will collaborate to develop 200mm D-Mode GaN power epiwafers that will be developed at IQE's UK facilities. The collaboration marks a key milestone in IQE's strategy of diversification into the high-growth power market, first announced at its 2022 Capital Markets Day. 

 

MyHealthChecked 9.5p  £4.9m (MHC.L) 

The consumer home-testing healthcare company announces its unaudited half-year report for the six months ended 30 June 2023. The Company announced revenue of £2.5m, a decrease of 74% (H1 2022: £9.8m), and an adjusted EBITDA loss of £296k (H1 2022 profit £372k). The Group has cash balance of £5m. The Group continued its investment into its IT infrastructure to support customer facing relationships and has launched a range of wellness tests into a UK top pharmacy retailer. The Group expects H2 trading on wellness tests to be broadly in line with its run rate. 

 

Poolbeg Pharma* 7.1p  £35.5m (POLB.L) 

A clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need announces that the opposition to one of its European patents (Immunomodulator I) that was previously filed by a third party is to be withdrawn. The Company will be communicating with the European Patent Office (EPO) regarding the necessity of continuing with the scheduled hearing in November. Based on specialist advice received, and the fact that the patent went through an extensive examination process prior to being granted by the EPO, Poolbeg continues to have full confidence in the validity and strength of the patent and will defend its intellectual property to the extent required. 

 

SpaceandPeople 92.5p  £1.8m (SAL.L) 

The retail, promotional and brand experience specialist, announces a further extension to its commercialisation agreement with Network Rail for the provision of exhibitions, events and distribution activity until 30 September 2024. The Agreement continues to cover Network Rail's portfolio of major London and regional railway stations (including London King's Cross, London Waterloo, London Paddington, Birmingham New Street and Glasgow Central) as well as Victoria Place Shopping Centre in London, providing access to many of the highest footfall venues and prestigious spaces in the United Kingdom. 

 

Surgical Innovations 1.3p  £12.1m (SUN.L) 

The designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery reports its unaudited financial results for the six-month period ended 30 June 2023 (2023 H1). Revenues increased 4.4% on prior year to £5.65m (2022 H1: £5.41m), however, adjusted EBITDA reduced by 96% to £0.01m (2022 H1: £0.29m). The Company announces adjusted operating loss of £0.28m (2022 H1: £0.01m profit) and holds net cash at the period end of £0.38m and has gross cash headroom of £2.41m. The Company initiated its operational review in Q2 to identify supply chain efficiencies to increase productivity and their transition to MDR remains on track whilst the Company has achieved the UKCA mark. 

 

Time Finance 27.5p  £25.4m (TIME.L) 

The specialist finance provider announces the appointments of Tracy Watkinson and Paul Hird as Independent Non-Executive Directors of the Group with immediate effect. Tracy is an accomplished executive with more than twenty years of finance and commercial experience, and currently serves as Chief Operating Officer of Finance at NatWest Group. Paul has a background of over thirty years in the finance sector, most recently as co-founder and Chief Executive of Leumi ABL, an asset-based lender. 

 

Water Intelligence 375p £65.1m (WATR.L) 

A multinational provider of precision, minimally-invasive leak detection and remediation solutions for both potable and non-potable water provides its unaudited interim results for the period ended 30 June 2023. Revenue increased by 9% to $38.7m (1H 2022: $35.6m), as a result adjusted EBITDA increased by 12% to $7.7m (1H 2022: $6.9m). Adjusted profit before tax increased by 18% to $5.4m (1H 2022: 4.6m) and the Company holds cash and cash equivalents of $18.7m at 30 June. Results are in line with market expectations and the Group continues to grow in its long run growth plan. 

 

* A corporate client of Hybridan LLP

** Arranged by most recent first

*** Alphabetically arranged

 

Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II       Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.